|
pubmed:abstractText |
The HIV/AIDS epidemic and the resultant therapeutic efforts have continued to evolve over the last several years. The continued challenges in vaccine development, the growing longevity of the patient population and the emergence of resistant strains to current highly active antiretroviral therapy necessitate the development of new, effective therapeutics which target novel mechanism of actions. CCR5, a member of the GPCR superfamily, plays a key role as a co-receptor during the HIV viral entry process. The utility of CCR5 antagonists in the clinical setting has been validated, culminating in the launch of maraviroc (Selzentry by Pfizer (New York, NY, USA) in 2007.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Roche Palo Alto LLC, 3431 Hillview Ave., Palo Alto, CA 94304, USA. hanbiaoyang@gmail.com
|
